The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...

People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical decline is evident, a study found. While measures of processing ...

Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review ...

PTC Therapeutics, Inc. (NASDAQ:PTCT) on Monday announced results from the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Stage 2 and Stage 3 Huntington’s disease (HD) patients. Huntington’s disease is ...

The following is a summary of “Measuring cognitive change in secondary progressive MS: an analysis of the ASCEND cognition substudy,” published in the April 2025 issue of Journal of Neurology by ...

Background: Neurocognitive impairment is linked to aging, vascular stiffness, and HIV infection. The role of vascular stiffness in neurocognitive functioning among men with HIV (MWH) remains unclear.

COGNITIVE decline in relapsing-remitting multiple sclerosis (RRMS) can progress independently of both relapses and MRI-detected disease activity, challenging traditional methods of monitoring MS ...

Credit: Getty Images In an interim analysis of ENLIGHTEN, researchers described changes in cognitive function over 1 year in patients with MS. For the Symbol Digit Modalities Test, clinically ...

Digit one in ASL pixel perfect white linear icon for dark theme. Nonverbal communication. Gesture language. Thin line illustration. Isolated symbol for night mode. Editable stroke. Arial font used ...

Please provide your email address to receive an email when new articles are posted on . Prolonged REM sleep latency was associated with three key Alzheimer’s-specific pathological changes. REM sleep ...

Beta-blocker use is associated with a 34% reduction of onset in premanifest Huntington disease (preHD) and slower progression in early motor-manifest Huntington disease (mmHD), new research shows. In ...